a Department of Molecular Medicine and Biopharmaceutical Sciences, College of Pharmacy , Seoul National University , Seoul , South Korea.
b Tumor Microenvironment Global Core Research Center, College of Pharmacy , Seoul National University , Seoul , South Korea.
Free Radic Res. 2019 Mar;53(3):335-347. doi: 10.1080/10715762.2019.1576867. Epub 2019 Mar 1.
15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is the key enzyme that catalyses the conversion of prostaglandin E to a keto metabolite. The expression of 15-PGDH is ubiquitously repressed in various human malignancies. However, the molecular mechanisms underlying down-regulation of 15-PGDH expression remain largely unknown. 15-Deoxy-△-prostaglandin J (15d-PGJ), an endogenous ligand of peroxisome proliferator-activated receptor γ, has been reported to have anti-inflammatory and anticarcinogenic activities. In the present study, we have found that 15d-PGJ induces expression and catalytic activity of 15-PGDH in human breast cancer (MDA-MB-231) cells. 15d-PGJ decreased the level of CpG methylation in the 15-PGDH promoter in MDA-MB-231 cells as determined by the bisulphite genome sequencing and methyl-specific PCR. 15d-PGJ inhibited the catalytic activity of methyltransferase 1 (DNMT1) but did not influence its expression. Biotinylated 15d-PGJ directly interacted with DNMT1 and reduced its catalytic activity. Chromatin-immunoprecipitation analysis revealed that 15d-PGJ significantly attenuated DNMT1 binding to the activator protein-1 transcription factor present in the 15-PGDH promoter region. A nonelectrophilic analogue 9,10-dihydro-15d-PGJ failed to suppress the methylation of CpG islands present in 15-PGDH promoter and did not affect both DNMT1 activity and 15-PGDH expression. These findings suggest that the α,β-unsaturated carbonyl group present in 15d-PGJ is essential for its inactivation on DNMT1 and expression of 15-PGDH. In conclusion, 15d-PGJ plays as a hypomethylating agent through direct interaction with DNMT1 and consequently suppresses DNMT1-mediated hypermethylation of 15-PGDH promoter, leading to up-regulation of 15-PGDH expression.
15-羟基前列腺素脱氢酶(15-PGDH)是催化前列腺素 E 转化为酮代谢物的关键酶。15-PGDH 的表达在各种人类恶性肿瘤中普遍受到抑制。然而,15-PGDH 表达下调的分子机制在很大程度上尚不清楚。15-脱氧-△-前列腺素 J(15d-PGJ)是过氧化物酶体增殖物激活受体 γ 的内源性配体,已被报道具有抗炎和抗癌活性。在本研究中,我们发现 15d-PGJ 诱导人乳腺癌(MDA-MB-231)细胞中 15-PGDH 的表达和催化活性。15d-PGJ 通过亚硫酸氢盐基因组测序和甲基特异性 PCR 降低 MDA-MB-231 细胞中 15-PGDH 启动子的 CpG 甲基化水平。15d-PGJ 抑制甲基转移酶 1(DNMT1)的催化活性,但不影响其表达。生物素化 15d-PGJ 直接与 DNMT1 相互作用并降低其催化活性。染色质免疫沉淀分析显示,15d-PGJ 显著减弱 DNMT1 与存在于 15-PGDH 启动子区域的激活蛋白-1 转录因子的结合。非亲电子类似物 9,10-二氢-15d-PGJ 不能抑制 15-PGDH 启动子中 CpG 岛的甲基化,也不影响 DNMT1 活性和 15-PGDH 表达。这些发现表明,15d-PGJ 中存在的α,β-不饱和羰基对于其对 DNMT1 的失活以及 15-PGDH 的表达至关重要。总之,15d-PGJ 通过与 DNMT1 的直接相互作用充当一种去甲基化剂,从而抑制 DNMT1 介导的 15-PGDH 启动子过度甲基化,导致 15-PGDH 表达上调。